Cabozantinib

Drug Profile

Cabozantinib

Alternative Names: BMS-907351; Cabometyx; Cabozantinib s-malate; Cometriq; XL-184

Latest Information Update: 04 Jan 2017

Price : $50

At a glance

  • Originator Exelixis
  • Developer Dana-Farber Cancer Institute; Duke University Medical Center; Exelixis; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Swedish Orphan Biovitrum
  • Class Anilides; Antineoplastics; Cyclopropanes; Quinolines; Small molecules
  • Mechanism of Action Proto oncogene protein c met inhibitors; Proto oncogene protein c ret inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal cell carcinoma; Thyroid cancer
  • Phase III Hepatocellular carcinoma
  • Phase II Bone metastases; Brain metastases; Breast cancer; Cholangiocarcinoma; Fallopian tube cancer; Merkel cell carcinoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Urogenital cancer
  • Phase I/II Multiple myeloma
  • Phase I Acute myeloid leukaemia; Cancer; Colorectal cancer; Solid tumours
  • No development reported Astrocytoma; Glioblastoma
  • Discontinued Prostate cancer

Most Recent Events

  • 22 Dec 2016 Exelixis amends its existing licensing agreement with Ipsen to commercialize and develop cabozantinib in Canada
  • 21 Dec 2016 Ipsen announces intention to submit NDA to Health Canada in 2017
  • 10 Oct 2016 Positive efficacy and adverse events data from the phase II CABOSUN trial in Renal cell carcinoma (First-line therapy, Late-stage disease, Metastatic disease, Treatment-naïve) presented at the European Society for Medical Oncology (ESMO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top